Dyslipidemia associated with greater risk of psoriasis development, reveals research

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-01-06 14:45 GMT | Update On 2025-01-07 07:04 GMT

Dyslipidemia associated with greater risk of psoriasis development, reveals research published in the Medicine (Baltimore).

The atherogenic index of plasma (AIP) is a significant indicator of lipid levels. This study aimed to investigate the association between psoriasis and AIP in adults. The association between AIP and psoriasis was investigated using multivariate logistic regression, and smoothing curve fitting utilizing data from the National Health and Nutrition Examination Survey 2009 to 2014. Subgroup analysis and interaction tests were employed to investigate whether this relationship was stable across populations.

The final sample included 8177 participants, representing approximately 60 million people in the US. Psoriasis among the AIP groups (quartile, Q1–Q4) was statistically significant (P < .05). In the minimally adjusted model, each 1-unit increase in AIP was associated with a 44% increase in the risk of developing psoriasis [1.44 (1.01, 2.20)]. Participants in the highest quartile of AIP had a 40% higher risk of developing psoriasis than those in the lowest quartile [1.40 (1.05, 2.10)]. In the male group, the risk of developing psoriasis increased by 0.86 points per 1 unit increase in AIP. AIP is positively associated with psoriasis in US adults. Our findings imply that AIP improves psoriasis prevention in the general population.

Reference:

Tuo Y, He J, Guo T. Associations between the atherogenic index of plasma and psoriasis among US adults: A cross-sectional study based on NHANES 2009 to 2014. Medicine (Baltimore). 2024 Dec 13;103(50):e40955. doi: 10.1097/MD.0000000000040955. PMID: 39686463; PMCID: PMC11651505.

Article Source : Medicine (Baltimore)

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Dyslipidemia associated with greater risk of psoriasis development, reveals research

Similar News

Atopic Eczema Significantly Increases Risk of Suicidal Thoughts, Major Study Reveals

Hidradenitis Suppurativa Linked to Higher Risk of Serious Eye Diseases: Study

Psoriasis Treatments Show No Impact on Blood Glucose Levels: Study

Biologic Therapy may Lower Malignancy Risk in Psoriasis, suggests study

Maternal Dietary Diversity Lowers Childhood Eczema Risk: Study

AOPT-LTL Therapy Improves Melasma via SCF/c-KIT Pathway Inhibition: Study Finds

Psoriatic Arthritis Patients Face Higher Burden of Metabolic Syndrome, Meta-Analysis Shows

Oral vs. Topical TXA: Comparable Effectiveness and Safety in treatment of Melasma